I've been obsessively tracking my insulin resistance markers since starting tirzepatide 12 months ago. My endocrinologist orders a full metabolic panel every 3 months and I want to share the trajectory because I think HOMA-IR is an underappreciated metric.

Background: 44F, BMI 36.8 at start, prediabetes (A1C 6.2%), PCOS. Strong family history of T2DM.

My HOMA-IR went from 9.5 (severely insulin resistant) to 1.5 (normal, optimal is <2.0). That is a 84% improvement. My fasting insulin went from 32.6 to 7.2 µIU/mL, which my endocrinologist says is the single best indicator that my metabolic health has fundamentally changed.

For context, I was told I was "almost certainly going to develop diabetes within 5 years" at my baseline visit. My endo now says my diabetes risk is back to population average. That prognosis change is staggering.

Your HOMA-IR trajectory is excellent and illustrates a point I try to make to every patient: fasting insulin is a much earlier and more sensitive marker of metabolic dysfunction than fasting glucose or A1C.

Here's why: in the natural history of insulin resistance, fasting glucose and A1C are maintained in the normal or near-normal range for years by compensatory hyperinsulinemia. Your baseline fasting glucose of 118 (prediabetic) was actually being "held down" by your insulin of 32.6 — your pancreas was working overtime to keep glucose in check.

The progression typically looks like this:

1. Stage 1 (years 1-5): Normal glucose, rising insulin. HOMA-IR elevated, A1C normal.
2. Stage 2 (years 5-10): Prediabetic glucose (100-125). Insulin still elevated or beginning to fail. A1C 5.7-6.4%.
3. Stage 3: Overt T2DM. Glucose >126, A1C ≥6.5%. Insulin may be high (resistant) or declining (beta-cell exhaustion).

You caught it at Stage 2 and reversed it. By normalizing fasting insulin to 7.2, you've eliminated the compensatory hyperinsulinemia, which means your peripheral tissues (muscle, liver, adipose) are once again responding to insulin normally. This is genuine disease reversal.

The PCOS component is also relevant: insulin resistance drives ovarian androgen production, so many patients see improvement in PCOS symptoms (menstrual regularity, acne, hirsutism) as HOMA-IR normalizes.

Beautifully demonstrated case. I want to highlight a practical point: most standard metabolic panels do NOT include fasting insulin. You have to specifically request it. If you're tracking metabolic health on GLP-1 therapy, ask your doctor to order:

• Fasting glucose (standard)
• Fasting insulin (must be specifically ordered)
• A1C (standard)
• Calculate HOMA-IR: [fasting insulin × fasting glucose] / 405

Many labs will calculate HOMA-IR automatically if both fasting glucose and insulin are ordered. If not, the formula is simple enough to calculate yourself.

Interpretation:

The OP went from "severe" to "normal" in 12 months. In my practice, I see HOMA-IR normalize in roughly 60-70% of patients who achieve >15% weight loss on GLP-1/GIP agonists.

And to answer the PCOS question — yes! My periods have become regular for the first time in my adult life. I've had 10 regular cycles in the past 12 months after averaging 4-5 per year for the past decade. My DHEA-S and total testosterone are also in the normal range for the first time. My endo and gynecologist are both attributing this to the insulin sensitization.

This is something that metformin was supposed to help with (I was on metformin 1500mg for 3 years for PCOS) but never fully achieved. Tirzepatide accomplished in months what metformin couldn't in years.

The relationship between insulin resistance and PCOS outcomes is well-established. Here's how insulin sensitization affects the PCOS hormonal milieu:

The OP's case is a perfect illustration of how insulin resistance is the common thread linking PCOS, metabolic syndrome, and cardiometabolic risk. Addressing the root cause (insulin resistance) resolves multiple downstream conditions simultaneously.